1. Centers for Disease Control and Prevention. Prevalence of Both Diagnosed and Undiagnosed Diabetes. https://www.cdc.gov/diabetes/data/statistics-report/diagnosed-undiagnosed.html. Accessed March 19, 2019.
2. Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.;JF Mosley;P T,2015
3. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes–A systematic review;K Rådholm;Diabetes Research and Clinical Practice,2018
4. US Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). https://www.fda.gov/downloads/Drugs/DrugSafety/UCM558427.pdf. Updated May 16, 2017. Accessed October 17, 2017.
5. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes;B Neal;N Engl J Med,2017